Anticorps Recombinant de lapin anti-HLA-DR

HLA-DR Recombinant Antibody for FC

Hôte / Isotype

Mouse / IgG2a

Réactivité testée

Humain

Applications

FC

Conjugaison

Biotin

CloneNo.

L243

N° de cat : Biotin-65560

Synonymes

HLA-DRA, HLA DRA, HLA DRA1, HLA DRB, HLA-DRA1



Applications testées

Résultats positifs en cytométrieCMSP humaines

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

Biotin-65560 cible HLA-DR dans les applications de FC et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Mouse / IgG2a
Clonalité Recombinant
Type Anticorps
Immunogène Human lymphoblastoid B-cell line RPMI 8866
Nom complet major histocompatibility complex, class II, DR alpha
Masse moléculaire calculée 254 aa, 29 kDa
Numéro d’acquisition GenBankBC032350
Symbole du gène HLA-DRA
Identification du gène (NCBI) 3122
Conjugaison Biotin
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

Informations générales

HLA-DR is a member of MHC class II molecules encoded by the human leukocyte antigen complex on the region 6p21.31 of chromosome 6. HLA-DR is composed of two non-covalently associated transmembrane glycoproteins (the α and β chains), and is primarily expressed on B lymphocytes, monocytes, dendritic cells and thymic epithelial cells (PMID: 33125816). HLA-DR participates in the antigen presentation to CD4+ or CD8+ T cells and is postulated as a general biomarker of sepsis-induced immunosuppression (PMID: 28199206, 32421903).

Protocole

Product Specific Protocols
FC protocol for Biotin HLA-DR antibody Biotin-65560Download protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}